









市场行情
/
股票
/
nasdaq-phvs
/

Pharvaris NV

PHVS

25.630USD

-0.370-1.42%

收盘 01/14, 16:00（美东）报价延迟15分钟

1.66B总市值

亏损市盈率 TTM



Pharvaris NV

25.630

-0.370-1.42%

概览公司财务分析

概览

公司

财务

分析

关于 Pharvaris NV 公司

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Pharvaris NV简介



公司代码PHVS

公司名称Pharvaris NV

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

员工数量- -

证券类型Ordinary Share

年结日Feb 05

公司地址Emmy Noetherweg 2

城市LEIDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Netherlands

邮编2333 BK

电话31712036410

网址https://pharvaris.com/

公司代码PHVS

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

Pharvaris NV公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.48M

-26250.00%

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-18897.00%

Ms. Viviane Monges

Non-Executive Director

54.91K

+23186.00%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+318.00%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+28436.00%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

+800.00%

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

Dr. Anne Lesage, Ph.D.

Co-Founder, Chief Early Development Officer

Dr. Morgan Conn, Ph.D.

Chief Business Officer

名称

名称/职务

职务

持股

持股变动

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.48M

-26250.00%

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-18897.00%

Ms. Viviane Monges

Non-Executive Director

54.91K

+23186.00%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+318.00%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+28436.00%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

+800.00%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

General Atlantic LLC

12.54%

Fidelity Management & Research Company LLC

9.99%

Foresite Capital Management, LLC

7.46%

VenBio Partners LLC

7.24%

Viking Global Investors LP

5.70%

其他

57.07%

持股股东

占比

General Atlantic LLC

12.54%

Fidelity Management & Research Company LLC

9.99%

Foresite Capital Management, LLC

7.46%

VenBio Partners LLC

7.24%

Viking Global Investors LP

5.70%

其他

57.07%

股东类型

持股股东

占比

Private Equity

33.13%

Hedge Fund

22.83%

Investment Advisor

18.10%

Venture Capital

11.99%

Investment Advisor/Hedge Fund

9.82%

Individual Investor

5.32%

Research Firm

0.17%

Bank and Trust

0.07%

Pension Fund

0.05%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

140

61.63M

96.21%

+11.08M

2025Q3

118

49.64M

77.50%

-950.63K

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

52.08M

96.43%

-141.66K

2024Q1

49.63M

98.30%

-831.88K

2023Q4

47.76M

94.74%

+8.60M

2023Q3

36.05M

91.51%

-2.92M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

General Atlantic LLC

8.03M

12.54%

+500.00K

+6.64%

Sep 30, 2025

Fidelity Management & Research Company LLC

6.40M

9.99%

+976.76K

+18.01%

Sep 30, 2025

Foresite Capital Management, LLC

4.78M

7.46%

+368.00K

+8.34%

Sep 30, 2025

VenBio Partners LLC

4.64M

7.24%

+350.00K

+8.16%

Sep 30, 2025

Viking Global Investors LP

3.65M

5.7%

Sep 30, 2025

EQT Life Sciences

3.56M

5.55%

Apr 01, 2025

EQT Partners AB

3.42M

5.35%

+3.42M

Sep 30, 2025

Bain Capital Life Sciences Investors, LLC

3.18M

4.97%

-122.11K

-3.70%

Sep 30, 2025

Deerfield Management Company, L.P.

2.44M

3.81%

+425.00K

+21.07%

Sep 30, 2025

Commodore Capital LP

2.42M

3.78%

+507.04K

+26.53%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ALPS Medical Breakthroughs ETF

0.59%

iShares MSCI Netherlands ETF

0.23%

SPDR S&P International Small Cap ETF

0.08%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

Fidelity Nasdaq Composite Index ETF

0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0.01%

Avantis International Small Cap Equity ETF

First Trust IPOX Europe Equity Opportunities ETF

Virtus LifeSci Biotech Clinical Trials ETF

占比0.87%

ALPS Medical Breakthroughs ETF

占比0.59%

iShares MSCI Netherlands ETF

占比0.23%

SPDR S&P International Small Cap ETF

占比0.08%

iShares MSCI Europe Small-Cap ETF

占比0.04%

iShares MSCI EAFE Small-Cap ETF

占比0.02%

Fidelity Nasdaq Composite Index ETF

占比0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

占比0.01%

Avantis International Small Cap Equity ETF

占比0%

First Trust IPOX Europe Equity Opportunities ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据

常见问题

Pharvaris NV的前五大股东是谁？



Pharvaris NV 的前五大股东如下：
General Atlantic LLC持有股份：8.03M，占总股份比例：12.54%。
Fidelity Management & Research Company LLC持有股份：6.40M，占总股份比例：9.99%。
Foresite Capital Management, LLC持有股份：4.78M，占总股份比例：7.46%。
VenBio Partners LLC持有股份：4.64M，占总股份比例：7.24%。
Viking Global Investors LP持有股份：3.65M，占总股份比例：5.70%。